CymaBay Therapeutics (CBAY) Misses Q4 EPS by 40c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to CymaBay Therapeutics (CBAY) Misses Q4 EPS by 40c

CymaBay Reports Fourth Quarter and Full Year 2014 Financial Results

March 18, 2015 4:01 PM EDT

NEWARK, CA -- (Marketwired) -- 03/18/15 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders, today provided recent corporate highlights and announced financial results for the quarter and year ended December 31, 2014.

"With the completion of five Phase 2 studies of arhalofenate in gout, we have established arhalofenate's potential as the first dual acting Urate Lowering Anti-Flare Therapy, or ULAFT. These studies have enabled us to finalize the target profile and plan a clear path... More